Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars: Eight Is Already More Than Enough For FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER's Division of Therapeutic Proteins has received eight pre-IND and IND applications for biosimilar products, and feels a "tremendous strain."

You may also be interested in...



Biosimilars Development Should Target “Residual Uncertainty,” FDA Says

Agency officials stress their willingness to work with applicants, while an industry expert urges comparative testing in the setting or settings most sensitive to potential differences.

FDA, EMA Seek Biosimilar Pathway Convergence

The deputy director of FDA's Europe Office discusses the collaboration between FDA and the European Medicines Agency; the agencies are looking for ways to develop a common biosimilar development program.

FDA, EMA Seek Biosimilar Pathway Convergence

The deputy director of FDA's Europe Office discusses the collaboration between FDA and the European Medicines Agency; the agencies are looking for ways to develop a common biosimilar development program.

Related Content

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel